Cargando…
Choosing the Right Treatment Option for the Right R/M HNSCC Patient: Should We Adhere to PFE for First-Line Therapy?
BACKGROUND: The landmark EXTREME trial established cisplatin, 5-fluorouracil and cetuximab (PFE) as first-line chemotherapy (1L-ChT) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). We were interested in outcome differences of R/M HNSCC in 1L-ChT and factors influencing ou...
Autores principales: | Lübbers, Katharina, Pavlychenko, Mykola, Wald, Theresa, Wiegand, Susanne, Dietz, Andreas, Zebralla, Veit, Wichmann, Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329655/ https://www.ncbi.nlm.nih.gov/pubmed/34354955 http://dx.doi.org/10.3389/fonc.2021.715297 |
Ejemplares similares
-
Standardized Diagnostic Workup and Patient-Centered Decision Making for Surgery and Neck Dissection Followed by Risk-Factor Adapted Adjuvant Therapy Improve Loco-Regional Control in Local Advanced Oral Squamous Cell Carcinoma
por: Wichmann, Gunnar, et al.
Publicado: (2021) -
Frailty Assessed with FRAIL Scale and G8 Questionnaire Predicts Severe Postoperative Complications in Patients Receiving Major Head and Neck Surgery
por: Kunz, Viktor, et al.
Publicado: (2022) -
Web-Based Patient-Reported Outcomes for ENT Patients—Evaluation of the Status Quo, Patients’ View, and Future Perspectives
por: Wald, Theresa, et al.
Publicado: (2022) -
Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome
por: Röhl, Louisa, et al.
Publicado: (2023) -
Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Siemert, Julia, et al.
Publicado: (2021)